FDA approves ultrasound fibroid therapy

The US Food and Drug Administration (FDA) has approved the first noninvasive, potentially ablative therapy for uterine fibroids, called the ExAblate 2000 System that is the combination of magnetic resonance imaging (MRI) and ultrasound technology that offers selected patients a less invasive alternative to surgery. The treatment is an outpatient procedure with shorter recovery time and benefits women who report symptoms associated with fibroid bulk, back and bladder pressure.